0000000000726561

AUTHOR

Salvatore De Rosa

0000-0001-5388-942x

showing 15 related works from this author

Synthesis and evaluation of diverse thio avarol derivatives as potential UVB photoprotective candidates.

2007

Semisynthesis of 13 new thio avarol derivatives (4-16) and in vitro evaluation on the photodamage response induced by UVB irradiation are described. Their ability to inhibit NF-kappaB activation and TNF-alpha generation in HaCaT cells as well as their antioxidant capacity in human neutrophils has also been studied. Among them we have identified two monophenyl thio avarol derivatives (4-5) lacking cytotoxicity which can be considered promising UVB photoprotective agents through the potent inhibition of NF-kappaB activation with a mild antioxidant pharmacological profile.

AntioxidantMagnetic Resonance SpectroscopyNeutrophilsPhotochemistryUltraviolet Raysmedicine.medical_treatmentChemistry PharmaceuticalClinical BiochemistryMolecular ConformationPharmaceutical ScienceThio-BiochemistryChemical synthesisAntioxidantsCell Line TumorDrug DiscoverymedicineHumansCytotoxicityMolecular Biologyintegumentary systemChemistryTumor Necrosis Factor-alphaOrganic ChemistryNF-kappa BSemisynthesisIn vitroHaCaTmedicine.anatomical_structureBiochemistryModels ChemicalDrug DesignMolecular MedicineKeratinocyteReactive Oxygen SpeciesSesquiterpenesBioorganicmedicinal chemistry letters
researchProduct

Suppression of leukotriene B4 and tumour necrosis factor alpha release in acute inflammatory responses by novel prenylated hydroquinone derivatives.

1998

A series of prenyl hydroquinone derivatives synthesized as structural analogs of marine products were tested for their effects on inflammatory responses in vitro and in vivo. 2-Prenyl-1,4-hydroquinone (H1), 2-diprenyl-1,4-hydroquinone (H2), 2-triprenyl-1,4-hydroquinone (H3) and 2-tetraprenyl-1,4-hydroquinone (H4) scavenged reactive oxygen species and inhibited 5-lipoxygenase (5-LO) activity in human neutrophils. The inhibition of 5-LO activity was demonstrated in vivo in the mouse air pouch injected with zymosan and arachidonic acid-induced ear inflammation. The four compounds suppressed the production of tumour necrosis factor alpha (TNFalpha) in J774 cells stimulated with lipopolysacchari…

MaleNecrosisLipopolysaccharideLeukotriene B4Anti-Inflammatory AgentsPharmacologyLeukotriene B4Dinoprostonechemistry.chemical_compoundMiceIn vivomedicineAnimalsEdemaHumansCells CulturedNitritesPharmacologyInflammationArachidonic AcidbiologyTumor Necrosis Factor-alphaZymosanGeneral MedicineHydroquinonesNitric oxide synthasechemistryBiochemistryDepression ChemicalArachidonate 5-lipoxygenaseLuminescent Measurementsbiology.proteinTumor necrosis factor alphamedicine.symptomNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Synthesis of the neurotoxin quinolinic acid in apoptotic tissue from Suberites domuncula: cell biological, molecular biological and chemical analyses

2002

Sessile marine animals, such as sponges, are prone to infection by prokaryotic as well as by eukaryotic attacking organisms. In the present study we document for the first time that in tissue from sponges which underwent apoptosis, a toxic compound is produced which very likely controls the elimination of the dying tissue. The marine sponge Suberites domuncula develops in the field occasionally apoptotic tissue areas which are rapidly eliminated. In the present study apoptosis was induced in S. domuncula by exposing the specimens in aquaria to 5 µg/ml Dip or by maintaining the sponges for 3 - 5 days under non-aeration conditions. After that treatment only one eukaryotic epibiont, the mollus…

chemistry.chemical_classificationbiologyCell growthCellbiology.organism_classificationApplied Microbiology and BiotechnologyBioactive compoundMicrobiologySuberites domunculachemistry.chemical_compoundSpongemedicine.anatomical_structureEnzymechemistryBiochemistryApoptosismedicineQuinolinic acid
researchProduct

Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-αby inhibiting nuclear factor-κB activation

2003

The marine product cacospongionolide B, a sesterterpene isolated from the Mediterranean sponge Fasciospongia cavernosa, is an inhibitor of secretory phospholipase A2 with anti-inflammatory properties. In this work, we have studied the mechanism of action of this compound in the inflammatory response induced by zymosan in primary cells and in the mouse air pouch. In mouse peritoneal macrophages, cacospongionolide B was able to downregulate the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), resulting in decreased production of NO and prostaglandin E2 (PGE2). This compound also reduced tumour necrosis factor-α (TNF-α) mRNA expression and TNF-α levels. Cacosp…

Pharmacologymedicine.medical_specialtyNecrosisbiologyZymosanNFKB1Molecular biologyNitric oxide synthasechemistry.chemical_compoundEndocrinologyMechanism of actionchemistryInternal medicinemedicinebiology.proteinTumor necrosis factor alphamedicine.symptomProstaglandin E2Transcription factormedicine.drugBritish Journal of Pharmacology
researchProduct

Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2

1999

Cacospongionolide B is a novel marine metabolite isolated from the sponge Fasciospongia cavernosa. In in vitro studies, this compound inhibited phospholipase A2 (PLA2), showing selectivity for secretory PLA2 (sPLA2) versus cytosolic PLA2 (cPLA2), and its potency on the human synovial enzyme (group II) was similar to that of manoalide. This activity was confirmed in vivo in the 8 h zymosan-injected rat air pouch, on the secretory enzyme accumulating in the pouch exudate. Cacospongionolide B, that is bioavailable when is given orally, reduced the elevated levels of sPLA2 present in paw homogenates of rats with adjuvant arthritis. This marine metabolite showed topical anti-inflammatory activit…

PharmacologybiologyMetaboliteZymosanBiological activityPharmacologyManoalidechemistry.chemical_compoundPhospholipase A2EicosanoidchemistryEnzyme inhibitorIn vivoImmunologybiology.proteinBritish Journal of Pharmacology
researchProduct

A New Cacospongionolide Inhibitor of Human Secretory Phospholipase A2 from the Tyrrhenian Sponge Fasciospongia cavernosa and Absolute Configuration o…

1998

A new inhibitor of human secretory phospholipase A2 (PLA2), cacospongionolide E (4a), has been isolated from the Tyrrhenian sponge Fasciospongia cavernosa. The structure was proposed on the basis of spectroscopic data and by chemical transformations. The absolute configuration of cacospongionolides 2a-4a was established using the modified Mosher's method. Cacospongionolide E was the most potent inhibitor toward human synovial PLA2, showing higher potency than the reference compound manoalide and exerting no signs of toxicity on human neutrophils. It showed high activity in the Artemia salina bioassay and moderate toxicity in the fish (Gambusia affinis) lethality assay.

Magnetic Resonance SpectroscopySpectrophotometry InfraredMolecular ConformationPharmaceutical ScienceMass SpectrometryPhospholipases AAnalytical ChemistryCyprinodontiformesManoalidechemistry.chemical_compoundPhospholipase A2Synovial FluidDrug DiscoveryAnimalsHumansBioassayEnzyme InhibitorsFuransPancreasPyransPharmacologybiologyVenomsOrganic ChemistryAbsolute configurationBiological activitybiology.organism_classificationPoriferaPhospholipases A2SpongeComplementary and alternative medicinechemistryBiochemistryEnzyme inhibitorbiology.proteinMolecular MedicineSpectrophotometry UltravioletDrug Screening Assays AntitumorArtemia salinaJournal of Natural Products
researchProduct

Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation.

2006

Contains fulltext : 49512schalkwijk.pdf (Publisher’s version ) (Closed access) Avarol, a marine sesquiterpenoid hydroquinone, and 14 avarol derivatives have shown interesting anti-inflammatory properties in previous studies. In this study, avarol and derivatives were evaluated in high-throughput keratinocyte culture models using cytokeratin 10 and SKALP/Elafin expression as markers for respectively normal and psoriatic differentiation. Avarol and five of its derivatives (5, 10, 13, 14 and 15) were selected for further study. Only 10, 13, 14 and 15 were able to inhibit keratinocyte cell growth. Changes in expression levels of 22 genes were assessed by quantitative real time PCR (qPCR). From …

KeratinocytesDrug Evaluation PreclinicalAntineoplastic AgentsEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesBiologyGeneral Biochemistry Genetics and Molecular BiologyDownregulation and upregulationTranslational research [ONCOL 3]DysideaGene expressionDithranolmedicineAnimalsHumansPsoriasisRNA MessengerGeneral Pharmacology Toxicology and PharmaceuticsCells CulturedCell ProliferationChronic inflammation and autoimmunity [UMCN 4.2]Messenger RNATumor Necrosis Factor-alphaCell growthInterleukin-8Membrane ProteinsCell DifferentiationGeneral MedicineMolecular biologyElafinPathogenesis and modulation of inflammation [N4i 1]medicine.anatomical_structureMechanism of actionCyclooxygenase 2KeratinsClinical Pharmacology and physiology [CTR 2]medicine.symptomKeratinocyteSesquiterpenesInfection and autoimmunity [NCMLS 1]Elafinmedicine.drug
researchProduct

Potential Antipsoriatic Avarol Derivatives as Antioxidants and Inhibitors of PGE2 Generation and Proliferation in the HaCaT Cell Line

2004

The synthesis and structure-activity relationships for a series of 14 new avarol derivatives as antioxidants and inhibitors of cell proliferation and PGE(2) generation in human keratinocytes are described. Compound 6 (thiosalicylic derivative) was the most potent inhibitor of superoxide generation in human neutrophils and also potently inhibited PGE(2) generation in the human keratinocyte HaCaT cell line. Compound 7(3'-methylaminoavarone) presented the best antiproliferative profile, by the inhibition of (3)H-thymidine incorporation in HaCaT cells, with potency similar to the reference compound anthralin. None of the avarol derivatives showed any sign of cytotoxicity measured as LDH release…

KeratinocytesPharmaceutical ScienceAntioxidantsDinoprostoneAnalytical ChemistryInhibitory Concentration 50Structure-Activity Relationshipchemistry.chemical_compoundDrug DiscoverymedicineHumansStructure–activity relationshipCytotoxicityPharmacologyL-Lactate DehydrogenaseSuperoxideCell growthOrganic ChemistryFree Radical ScavengersSalicylatesIn vitroHaCaTmedicine.anatomical_structureItalyComplementary and alternative medicinechemistryBiochemistryCell cultureMolecular MedicineKeratinocyteSesquiterpenesJournal of Natural Products
researchProduct

Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A2 activity and some inflammatory responses.

1995

Three 2-polyprenyl-1,4-hydroquinone derivatives (2-heptaprenyl-1,4-hydroquinone: IS1, 2-octaprenyl-1,4-hydroquinone: IS2 and 2-[24-hydroxy]-octaprenyl-1,4-hydroquinone: IS3) isolated from the Mediterranean sponge Ircinia spinosula, were evaluated for effects on phospholipase A2 activity of different origin (Naja naja venom, human recombinant synovial fluid and bee venom), as well as on human neutrophil function and mouse ear oedema induced by 12-O-tetradecanoylphorbol 13-acetate (TPA). IS1 interacted minimally with these responses. In contrast, IS2 and IS3 inhibited human recombinant synovial phospholipase A2 in a concentration-dependent manner, with minor effects on the rest of the enzymes…

Blood PlateletsLeukocyte migrationLeukotriene B4Cell SurvivalNeutrophilsPharmacologyBiologyIn Vitro TechniquesLeukotriene B4Phospholipases Achemistry.chemical_compoundMicePhospholipase A2SuperoxidesMicrosomesSynovial fluidAnimalsEdemaHumansPharmacologyPhospholipase AL-Lactate DehydrogenasePancreatic ElastaseAnti-Inflammatory Agents Non-SteroidalDegranulationBiological activityHydroquinonesPoriferaThromboxane B2Thromboxane B2Phospholipases A2Biochemistrychemistrybiology.proteinTetradecanoylphorbol AcetateEuropean journal of pharmacology
researchProduct

Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin

1996

The marine product ircinin has been tested for its effects on secretory and cytosolic phospholipase A2 (PLA2) activities in vitro as well as for inhibition of cellular functions in human neutrophils and inflammatory responses in mice. Ircinin inhibited Naja naja venom, human synovial recombinant, bee venom and zymosan-injected rat air pouch PLA2 with IC50 values in the microM range, similar to those of the known inhibitor scalaradial. On the other hand, ircinin was less active on cytosolic PLA2 from human monocytes and decreased potently the release of LTB4 in human neutrophils. This marine product affected weakly human neutrophil functions like superoxide generation and degranulation. In t…

MaleSesterterpenesNeutrophilsAnti-Inflammatory AgentsInflammationPharmacologyPhospholipases AMicechemistry.chemical_compoundPhospholipase A2SuperoxidesIn vivomedicineAnimalsEdemaHumansPharmacologyAnalysis of VarianceDose-Response Relationship DrugbiologyTerpenesSuperoxideDegranulationGeneral MedicineLeukotriene A4In vitroPoriferaRatsPhospholipases A2CytosolchemistryBiochemistryMyeloperoxidasebiology.proteinHomosteroidsMarine Toxinslipids (amino acids peptides and proteins)medicine.symptomLeukocyte ElastaseNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Avarol inhibits TNF-a generation and NF-kB activation in human cells and in animal models

2007

Avarol is a marine sesquiterpenoid hydroquinone with interesting pharmacological properties including anti-inflammatory and antipsoriatic effects. In the present study we evaluated the pharmacological effect of avarol on some inflammatory parameters related to the pathogenesis of psoriasis. Avarol inhibited tumor necrosis factor-alpha (TNF-alpha) generation in stimulated human monocytes (IC(50) 1 microM) and TNF-alpha-induced activation of nuclear factor-kappaB (NF-kappaB)-DNA binding in keratinocytes. In the mouse air pouch model, administration of avarol produced a dose-dependent reduction of TNF-alpha generation (ED(50) 9.2 nmol/pouch) as well as of interleukin (IL)-1beta, prostaglandin …

Keratinocytesmedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAntineoplastic AgentsBiologyPharmacologyMonocytesGeneral Biochemistry Genetics and Molecular BiologyCell LineMicechemistry.chemical_compoundDownregulation and upregulationIn vivoInternal medicinemedicineAnimalsHumansPsoriasisGeneral Pharmacology Toxicology and PharmaceuticsPeroxidaseInflammationHyperplasiaDose-Response Relationship DrugTumor Necrosis Factor-alphaNF-kappa B p50 SubunitInterleukinNF-κBGeneral MedicineDisease Models AnimalEndocrinologymedicine.anatomical_structureEicosanoidchemistryTetradecanoylphorbol AcetateFemaleTumor necrosis factor alphaEpidermisInflammation MediatorsKeratinocyteSesquiterpenesProstaglandin E
researchProduct

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

2020

Abstract Aims To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7–32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3–70.3; P …

MaleMyocardial Infarction030204 cardiovascular system & hematologySettore MED/110302 clinical medicineAcute myocardial infarction Cardiac care units STEMI Aged Aged 80 and over COVID-19 Female Hospitalization Humans Italy Male Middle Aged SARS-CoV-2 Betacoronavirus Coronavirus Infections Myocardial Infarction Pandemics Pneumonia ViralCase fatality rate80 and overMedicine030212 general & internal medicineMyocardial infarctionViralAged 80 and overAcute myocardial infarction; Cardiac care units; COVID-19; SARS-CoV2; STEMI; Aged; Aged 80 and over; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Betacoronavirus; Coronavirus Infections; Myocardial Infarction; Pandemics; Pneumonia ViralMiddle AgedHospitalizationItalyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanmedicine.medical_specialtyPneumonia ViralFast Track Clinical ResearchCardiac care unitsAcute myocardial infarctionSTEMI03 medical and health sciencesBetacoronavirusCardiac care unitHumansAcute myocardial infarction; COVID-19; Cardiac care units; SARS-CoV2; STEMIcardiovascular diseasesPandemicsAgedBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19Pneumoniamedicine.diseaseacute myocardial infarction; cardiac care units; COVID-19; SARS-CoV2; STEMIConfidence intervalRelative riskEmergency medicineSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARESARS-CoV2Myocardial infarction complicationsObservational studyMyocardial infarction diagnosisbusinessComplication
researchProduct

Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease

2018

Cardiovascular diseases (CVD) including coronary artery disease (CAD) and ischemic heart disease (IHD) are the main cause of mortality in industrialized countries. Although it is well known that there is a difference in the risk of these diseases in women and men, current therapy does not consider the sexual dimorphism; i.e., differences in anatomical structures and metabolism of tissues. Here, we discuss how genetic, epigenetic, hormonal, cellular or molecular factors may explain the different CVD risk, especially in high-risk groups such as women with diabetes. We analyze whether sex may modify the effects of diabetes at risk of CAD. Finally, we discuss current diagnostic techniques in th…

medicine.medical_specialtyAnatomical structureslcsh:MedicineReviewDisease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusgendercell signalingsexSettore MED/05 - Patologia ClinicaMedicinecardiovascular diseasesCoronary atherosclerosis030304 developmental biology0303 health sciencesdiabetesbusiness.industrylcsh:Rbiomarkers; cell signaling; coronary artery disease; diabetes; gender; sex; womenbiomarkersGeneral Medicinemedicine.diseaseSexual dimorphismdiabeteCardiologybiomarkerwomenbusinessIschemic heartDeveloped countrycoronary artery diseaseJournal of Clinical Medicine
researchProduct

"Delirium Day": a nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool

2016

Background To date, delirium prevalence in adult acute hospital populations has been estimated generally from pooled findings of single-center studies and/or among specific patient populations. Furthermore, the number of participants in these studies has not exceeded a few hundred. To overcome these limitations, we have determined, in a multicenter study, the prevalence of delirium over a single day among a large population of patients admitted to acute and rehabilitation hospital wards in Italy. Methods This is a point prevalence study (called “Delirium Day”) including 1867 older patients (aged 65 years or more) across 108 acute and 12 rehabilitation wards in Italian hospitals. Delirium wa…

MaleCross-sectional studyHospitalized patientsPrevalence0302 clinical medicineSurveys and Questionnaires80 and overOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesProspective cohort studyMulticenterAcute hospital2. Zero hungerAged 80 and overMedicine(all)Medicine (all)Settore BIO/14General Medicine3. Good health4AT; Delirium; Hospital; Multicenter; Prevalence; Aged; Aged 80 and over; Cross-Sectional Studies; Delirium; Female; Humans; Inpatients; Italy; Logistic Models; Male; Odds Ratio; Prevalence; Prospective Studies; Surveys and QuestionnairesItalyFemalemedicine.symptomResearch ArticleRehabilitation hospitalmedicine.medical_specialty4AT; Delirium; Hospital; Multicenter; Prevalence; Aged; Aged 80 and over; Cross-Sectional Studies; Delirium; Female; Humans; Inpatients; Italy; Logistic Models; Male; Odds Ratio; Prevalence; Prospective Studies; Surveys and Questionnaires; Medicine (all)NO03 medical and health sciencesHospital4AT Delirium Hospital Multicenter Prevalence Aged Aged 80 and over Cross-Sectional Studies Delirium Female Humans Inpatients Italy Logistic Models Male Odds Ratio Prevalence Prospective Studies Surveys and Questionnairesmental disordersHumans4ATPsychiatry4AT; Delirium; Hospital; Multicenter; Prevalence;AgedInpatientsbusiness.industryDeliriumOdds ratio4AT; Delirium; Hospital; Multicenter; Prevalence; Medicine (all)Cross-Sectional StudiesLogistic ModelsEmergency medicineDeliriumDelirium; Prevalence; Hospital; Multicenter; 4ATbusiness030217 neurology & neurosurgery
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct